Background: Anti-RA33 antibodies and anti-CCP antibodies are highly specific markers for rheumatoid arthritis (RA), but are not detectable in all RA patients.

Anti-RA33 antibodies are directed to the heterogeneous nuclear ribonucleoprotein A2 (hnRNP-A2),while anti-CCP antibodies are directed to modified epitope on proteins that undergo conversion of amino acid arginine to citrullin by citrullination.

Objectives: The aim of this study was to show the correlation between anti-RA33 antibodies, anti-CCP antibodies and rheumatoid factor (RF) in terms of sensitivity and specificity for the diagnosis of rheumatoid arthritis in Iraqi patients.

Subjects and methods: This s

Zinc, Copper, Selenium, Magnesium, Manganese, Chromium, Iron, Nickel, Cobalt, Vanadium and Germanium were determined by atomic absorption spectrophotometer (AAS) in blood serum of patients with rheumatoid arthritis, (30) patients (14male and 16female) with age range (37-60) years compared with normal tensive control. The analysis of results showed that the mean value of concentration (Magnesium,  Manganese and Nickel) were significantly higher in patients with rheumatoid arthritis compared to that of healthy, while the mean levels of serum (Zinc, Copper, Selenium, Chromium, Iron, Cobalt and Germanium) were significantly lower than controls. There were no significant changes in overall mean concentration of serum Vanadium in patients

Introduction: Cardiovascular diseases are the main cause of death among type 2 diabetic patients. Higher levels of plasminogen activator urokinase receptor have been found to predict morbidity and mortality across acute and chronic diseases in the common populace. This study aims to explore the role of serum plasminogen activator urokinase receptor levels as a cardiometabolic risk factor among type 2 diabetic Iraqi patients. Methods: Seventy type 2 diabetic patients (40 male and 30 female) (mean age: 46.20±7.56 years) participated in this study; 35 patients were with cardiovascular disease and 35 were without cardiovascular disease; their ages range was 40-55 years. In addition, 30 individuals who apparently healthy were selected a

Rheumatoid arthritis (RA) is one of the autoimmune diseases characterized by the synovial inflammation which causes organs and tissues damage especially synovial tissues and joints. The study included 50 serum samples from patients with rheumatoid arthritis (RA) when compared with 50 serum samples from healthy individuals as control with age range 35 – 60 years (41.3 ± 2.4 years vs. 41.0 ± 2.0 years, respectively). ELISA technique was used to assess the Anti-cyclic citrullinated peptide IgG antibody (anti-CCP IgG Ab) level, anti-rheumatoid factor IgG antibody (anti-RF IgG) and anti-Cytomegalovirus (anti-CMV IgG) antibodies frequencies in the studied groups. The present findings demonstrated that all RA patients have 100% seropositive fr

This study was conducted to evaluate the prevalence rate of
toxoplasmosis among 294 rheumatoid arthritis (RA) patients treated with
methotrexate (MTX), 50 RA patients without treatment and 50 samples as
healthy control. Blood samples were collected and the presence of T.gondii
IgG and IgM antibodies was determined by using Enzyme linked
immunosorbent assay (ELISA). Tumor necrosis factor alpha (TNF-α) was
also estimated in serum of all subjects by using ELISA method too. The
seroprevalence of toxoplasmosis IgM and IgG in RA+MTX was
60(20.408%), and 98(33.33%), in RA patients 4(8%), and 18(36%) while,
it was 2(24%), 6(12%) in healthy group. Tumor necrosis factor alpha
(TNF-α) was also estimated in serum of a

Introduction and Aim: Forkhead box P3 (FOXP3) and interleukin-10 (IL-10) are the key regulators controlling the activity of Treg cells, which are crucial for maintaining immune tolerance and reducing autoimmune reactions. The objective of this study was to investigate the potential utility of elevated levels of FOXP3 and IL-10 gene expression as a diagnostic indicator in patients with rheumatoid arthritis (RA).   Materials and Methods: The study used quantitative polymerase chain reaction (qPCR) to examine the expression levels of FOXP3 and IL-10 transcripts in whole blood samples from Iraqi patients with rheumatoid arthritis. A group of healthy control subjects were also included in the study.   Results: In blood samples taken fr

 Rheumatoid arthritis (RA) was a chronic inflammatory autoimmune disease for long-term that primarily affects small joints and leads to chronic inflammation in synovial. The aimed of the study to identify the relationships among some serological markers (antibodies to citrullinated protein/peptide antigens (ACPAs), anti-mutated citrullinated vimentin (anti-MCV), anti-carbamylated protein (Anti-Carp), anti- heterogeneous nuclear ribonucleoproteins (anti-hnRNP) and Glucose-6-phosphate isomerase (GPI)) and early diagnosis of RA. The study involved (60) Patients of newly diagnosis with RA that divided in to two subgroups (30 RF positive and 30 RF negative) groups and 30 subjects as healthy control group. The serological data from serum

Serum samples were obtained from patients suffering from chronic Rheumatoid Arthritis (RA) disease. They were divided into three groups; 20 patients with RA taking biological treatment Etanercept (Enbrel), 20 patients with RA not taking biological treatment (disease modifying anti-rheumatic drug) and 10 people as healthy control group. The ages of these patients and control group were between 46-50 years old; one male and 19 female in each group. The samples were used for measuring the levels of Interleukin (IL)-1 Beta and Interleukin-10 using the Enzyme Linked Immunosorbent Assay technique. Both interleukins were at their highest levels in the group of RA patients treated with biological treatment followed by the RA patients group that

The study objective was to conduct Pharmacoeconomics study (cost-effective analysis) between infliximab reference (Remicade) and its biosimilar (Remsima) in patients with rheumatoid arthritis (RA) in Iraqi hospitals.

This is a retrospective multicenter pharmacoeconomic analysis conducted at two large teaching governmental hospitals in Baghdad, Iraq which provided infliximab to patients with RA. Data were collected from patient’s medical records and face-to-face interviews with the patients from December 2021 to April 2022.

The study included 57 patients with rheumatoid arthritis (RA).  The patients were categorized into two groups according to the type of infliximab they received over 30 weeks: 27 patients received